Literature DB >> 23141760

Regional HTA in Italy: promising or confusing?

Livio Garattini1, Katelijne van de Vooren, Alessandro Curto.   

Abstract

We assessed the actual implementation and achievements of regional HTA in Italy. We conducted a web-based analysis (updated until July 2012). Six key elements were identified: availability of official documents, existence of a specific workgroup, involvement of external organizations, formal funds for HTA, publication of HTA reports, and membership of HTA networks. Then, we searched all HTA reports retrieved by key words to analyze whether their contents included clinical efficacy, economic evaluation, legal issues, ethics and organization. Two researchers analyzed the information separately, as a double check. Sixteen regions have formally established a structured workgroup inside their organizations. Specific funding for HTA activities could be traced in six regions, web-available reports only in four. Around 91% of the total reports concerned drugs. Contents mostly focused on epidemiological and clinical issues, economic evaluation was often restricted to a brief analysis of costs. Only a few reports mentioned organizational implications; ethical, legal and social issues were lacking. This survey showed a very uneven picture of HTA in the Italian regions. As expected, not all the regions were able to perform HTA, probably on account of their wide differences in size, tradition and skills in the health care field.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23141760     DOI: 10.1016/j.healthpol.2012.10.010

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  3 in total

1.  HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2020-02

2.  Reimbursable drug classes and ceilings in Italy: why not only one?

Authors:  Livio Garattini; Alessandro Curto; Anna Padula
Journal:  Eur J Health Econ       Date:  2016-11

3.  Comparing access to orphan medicinal products in Europe.

Authors:  Bernarda Zamora; Francois Maignen; Phill O'Neill; Jorge Mestre-Ferrandiz; Martina Garau
Journal:  Orphanet J Rare Dis       Date:  2019-05-03       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.